Synthesis of anticonvulsive AMPA antagonists: 4-Oxo-10-substituted-imidazo[1,2- a]indeno[1,2- e]pyrazin-2-carboxylic acid derivatives

The overstimulation of excitatory amino acid receptors such as the glutamate AMPA receptor has been implicated in the physiopathogenesis of epilepsy as well as in acute and chronic neurodegenerative disorders. An original series of readily water soluble 4-oxo-10-substituted-imidazo[1,2- a]indeno[1,2...

Full description

Saved in:
Bibliographic Details
Published inBioorganic & medicinal chemistry letters Vol. 11; no. 9; pp. 1205 - 1210
Main Authors Stutzmann, Jean-Marie, Bohme, Georg Andrees, Boireau, Alain, Damour, Dominique, Debono, Marc Williams, Genevois-Borella, Arielle, Jimonet, Patrick, Pratt, Jeremy, Randle, John C.R, Ribeill, Yves, Vuilhorgne, Marc, Mignani, Serge
Format Journal Article
LanguageEnglish
Published Oxford Elsevier Ltd 07.05.2001
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The overstimulation of excitatory amino acid receptors such as the glutamate AMPA receptor has been implicated in the physiopathogenesis of epilepsy as well as in acute and chronic neurodegenerative disorders. An original series of readily water soluble 4-oxo-10-substituted-imidazo[1,2- a]indeno[1,2- e]pyrazin-2-carboxylic acid derivatives was synthesized. The most potent derivative 6a exhibited nanomolar binding affinity (IC 50=35 nM) and antagonist activity (IC 50=6 nM) at ionotropic AMPA receptor. This compound also demonstrated potent anticonvulsant properties in MES in mice and rats with long durations of action with ED 50 values in the 1–3 mg/kg dose range following ip and iv administration. The 4-oxo-imidazo[1,2- a]indeno[1,2- e]pyrazin-2-carboxylic acid 1 exhibited strong binding affinity for the AMPA receptor (IC 50=35 nM) and potent antagonist activity against electrophysiological responses (IC 50=6 nM). Compound 1 demonstrated also an anticonvulsant effect at low doses in MES test with ED 50 values between 1 and 3 mg/kg dose range following ip and iv administration (mouse) and extended long duration of action following iv administration (mouse and rats).
ISSN:0960-894X
1464-3405
DOI:10.1016/S0960-894X(01)00180-9